Back to top
more

Curis (CRIS)

(Delayed Data from NSDQ)

$14.47 USD

14.47
10,913

-0.05 (-0.34%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $14.57 +0.10 (0.69%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CRIS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Curis, Inc. [CRIS]

Reports for Purchase

Showing records 281 - 300 ( 302 total )

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 281

10/12/2010

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 282

10/11/2010

Daily Note

Pages: 3

Roche/Genentech Commences Operable BCC Study -Elects Not to Pursue Ovarian Cancer

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 283

08/11/2010

Daily Note

Pages: 8

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 284

08/10/2010

Company Report

Pages: 3

GDC-0449 IN OVARIAN CANCER REQUIRES MORE ANALYSIS - LOWERING TARGET

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 285

08/05/2010

Daily Note

Pages: 9

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 286

08/04/2010

Company Report

Pages: 3

2Q10 UPDATE - HEDGEHOG COULD SHINE WITH OVARIAN TRIAL DATA THIS MONTH

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 287

07/20/2010

Daily Note

Pages: 10

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 288

07/19/2010

Industry Report

Pages: 3

Life Sciences: R&R’s Week in Review.

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 289

07/07/2010

Daily Note

Pages: 8

MORNING SUMMARY.

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 290

07/06/2010

Company Report

Pages: 3

Debiopharm Reaches Milestone - Genentech Trials Favor Upside Potential

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 291

06/16/2010

Daily Note

Pages: 3

GDC-0449 Misses in mCRC - Hedgehog to Show True Potential for Success in Ovarian, BCC

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 292

06/11/2010

Daily Note

Pages: 6

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 293

06/09/2010

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 294

06/08/2010

Industry Report

Pages: 3

2010 ASCO Highlights Days 1 & 2.

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 295

06/07/2010

Daily Note

Pages: 17

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 50.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 296

05/10/2010

Industry Report

Pages: 9

CARDIOVASCULAR TRIALS USING ADIPOSE STEM CELLS SHOW POTENTIAL - LARGER STUDIES PLANNED

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 297

05/10/2010

Daily Note

Pages: 9

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 298

05/07/2010

Company Report

Pages: 3

1Q10 UPDATE - HEDGEHOG IN THE SPOTLIGHT - DATA TO DRIVE VALUATION

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 299

05/04/2010

Daily Note

Pages: 6

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Curis, Inc.

Industry: Medical - Biomedical and Genetics

Record: 300

05/03/2010

Daily Note

Pages: 3

Phase 1 Trial Evaluating "All-In-One" HDAC / EGFR / HER2 Inhibitor Completes Enrollment

Provider: RODMAN & RENSHAW, CO.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party